Working… Menu

Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01334307
Recruitment Status : Completed
First Posted : April 13, 2011
Last Update Posted : January 24, 2014
Information provided by (Responsible Party):
PneumRx, Inc.

Brief Summary:
The objective of this study is to demonstrate the safety and performance of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc. LVRC is used as a less invasive alternative to lung volume reduction surgery.

Condition or disease Intervention/treatment Phase
Emphysema Device: Lung Volume Reduction Coil (LVRC) (PneumRx) Device: Control Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 47 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial Of RePneu (LVRC) Endobronchial Coils For The Treatment Of Severe Emphysema With Hyperinflation (RESET Study)
Study Start Date : February 2010
Actual Primary Completion Date : June 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: Lung Volume Reduction Coil (LVRC)
Lung Volume Reduction Coil (LVRC)
Device: Lung Volume Reduction Coil (LVRC) (PneumRx)
Lung Volume Reduction Coil (LVRC)
Other Name: LVRD

Placebo Comparator: Control
Standard of Care
Device: Control
Standard of Care
Other Name: LVRC Control treatment is Standard of Care

Primary Outcome Measures :
  1. St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: three month Follow-Up Visit ]
    The primary efficacy endpoint will be the difference between treatment and control groups in the change in St. George's Respiratory Questionnaire (SGRQ) from Baseline (Pre-Treatment Visit) to the three month Follow-Up Visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient greater than or equal to 35 years of age
  • High resolution CT scan indicates unilateral or bilateral emphysema
  • High resolution CT scan indicates homogeneous or heterogeneous emphysema
  • Patient has post-bronchodilator FEV1 less than or equal to 45% predicted
  • Total Lung Capacity greater than 100% predicted
  • Patient has marked dyspnea scoring greater than or equal to 2 on mMRC scale of 0-4
  • Patient has stopped smoking for a minimum of 8 weeks prior to entering the study
  • Patient (and legal guardian if applicable) read, understood and signed the Informed Consent form

Exclusion Criteria:

  • Patient has a change in FEV1 greater than 20% post-bronchodilator
  • Patients DLCO less than 20% predicted
  • Patient has a history of recurrent clinically significant respiratory infection
  • Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure greater than 50mm Hg and/or evidenced by echocardiogram
  • Patient has an inability to walk greater than 140 meters (150 yards) in 6 minutes
  • Patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc
  • Patient is pregnant or lactating
  • Patient has an inability to tolerate bronchoscopy under heavy sedation or anesthesia
  • Patient has clinically significant bronchiectasis
  • Patient has giant bullae greater than 1/3 lung volume
  • Patient has had previous LVR surgery, lung transplant or lobectomy
  • Patient has been involved in other pulmonary drug studies with 30 days prior to this study
  • Patient is taking greater than 20 mg prednisone (or similar steroid) daily
  • Patient is on Plavix or has not been weaned off prior to procedure
  • Patient has other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01334307

Layout table for location information
United Kingdom
Glasgow, United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
Manchester, United Kingdom
Sponsors and Collaborators
PneumRx, Inc.
Layout table for investigator information
Principal Investigator: Pallav Shah, MD Chelsea and Westminster Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PneumRx, Inc. Identifier: NCT01334307     History of Changes
Other Study ID Numbers: CLN0008
First Posted: April 13, 2011    Key Record Dates
Last Update Posted: January 24, 2014
Last Verified: May 2012
Keywords provided by PneumRx, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases